This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma
Male or female ≥ 18 years and ≤ 75 years.
Written informed consent must be obtained prior to any screening procedures.
Patients with histologically confirmed relapsed or refractory peripheral T-cell Lymphoma.
Must have received and failed at least 2 but no more than 5 prior lines of therapies .
Diagnosis of Cutaneous T-cell lymphoma .
Symptomatic central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression.
Patients with severe hemophagocytic syndrome at screening.
Presence of uncontrolled third space effusion